noon glp-1 Noom Launches Microdose Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program Noom Launches GLP-1 Microdosing for

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.

The significant year-over-year (YoY) jump in GLP-1 coverage among the largest companies signals a key shift: the employer debate is moving from whether to cover weight loss drugs to how to do so sustainably.

Adults take 1 capsule daily, or as recommended by your healthcare practitioner, with 8 ounces of water or your favorite beverage

The GLP-1 receptor agonist market is projected to grow from $63.24 billion in 2026 to $161.40 billion by 2034, at a CAGR of 12.43% during the forecast period 20262034.

In addition, glucagon like peptide 1 (GLP-1) receptor agonists, dual GLP-1 receptor and GIP receptor agonists, and pramlintide can be administered by injection

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and observational real-life studies